Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...

Mayo Clinic researchers have developed a new tool that can estimate a person's risk of developing memory and thinking ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

There’s rarely good news about Alzheimer’s disease, but a failed study may open the door to more research about vascular ...

New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an early end of the trial extension.

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of ...

The number of deaths from Alzheimer's disease and other forms of dementia has reached its highest level since records began ...